Gilead Faces Delay Of "Three To Four Months" For Latest HIV Single-Pill Drug

If approved, the combination of Gilead's Truvada and J&J's TMC278 is still expected to launch this year, but impurities related to one component have resulted in a "refuse to file" letter from FDA.